Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heike Hofmann

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Emerging Infectious Diseases|November 27, 2013
Lack of MERS coronavirus neutralizing antibodies in humans, eastern province, Saudi ArabiaStefanie Gierer, Heike Hofmann-Winkler, Waleed H Albuali, et al.
The Journal of Infectious Diseases|October 31, 2020
Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 InfectionLisa Henss, Tatjana Scholz, Christine von Rhein, et al.
Cell Reports|July 16, 2021
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccinationMarkus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger, et al.
Journal of Virology|August 31, 2006
DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by plateletsChawaree Chaipan, Elizabeth J Soilleux, Peter Simpson, et al.
Cell|April 1, 2021
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodiesMarkus Hoffmann, Prerna Arora, Rüdiger Groß, et al.
Critical Care Explorations|November 23, 2020
Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First ObservationHeike Hofmann-Winkler, Onnen Moerer, Sabine Alt-Epping, et al.
Biorxiv : the Preprint Server for Biology|August 15, 2020
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activityMarkus Hoffmann, Heike Hofmann-Winkler, Joan C Smith, et al.
Virology|November 28, 2006
A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivoStefan Pöhlmann, Jan Münch, Sheriff Aziz, et al.
Ebiomedicine|March 7, 2021
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activityMarkus Hoffmann, Heike Hofmann-Winkler, Joan C Smith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 16, 2021
Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 VaccinationMetodi V Stankov, Anne Cossmann, Agnes Bonifacius, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Emerging Infectious Diseases|November 27, 2013
Lack of MERS coronavirus neutralizing antibodies in humans, eastern province, Saudi ArabiaStefanie Gierer, Heike Hofmann-Winkler, Waleed H Albuali, et al.
The Journal of Infectious Diseases|October 31, 2020
Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 InfectionLisa Henss, Tatjana Scholz, Christine von Rhein, et al.
Cell Reports|July 16, 2021
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccinationMarkus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger, et al.
Journal of Virology|August 31, 2006
DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by plateletsChawaree Chaipan, Elizabeth J Soilleux, Peter Simpson, et al.
Cell|April 1, 2021
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodiesMarkus Hoffmann, Prerna Arora, Rüdiger Groß, et al.
Critical Care Explorations|November 23, 2020
Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First ObservationHeike Hofmann-Winkler, Onnen Moerer, Sabine Alt-Epping, et al.
Biorxiv : the Preprint Server for Biology|August 15, 2020
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activityMarkus Hoffmann, Heike Hofmann-Winkler, Joan C Smith, et al.
Virology|November 28, 2006
A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivoStefan Pöhlmann, Jan Münch, Sheriff Aziz, et al.
Ebiomedicine|March 7, 2021
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activityMarkus Hoffmann, Heike Hofmann-Winkler, Joan C Smith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 16, 2021
Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 VaccinationMetodi V Stankov, Anne Cossmann, Agnes Bonifacius, et al.
Pageof 7